We report the case of a 34-year-old woman affected by breast cancer that had metastasized to the bone. She had been treated with oral cyclophosphamide and methotrexate (metronomic chemotherapy) and achieved 3.5 years of clinical remission. To our knowledge, this is the first description of such a prolonged response to therapy. This case report adds weight to known data on metronomic treatment and supports further investigation of this therapy.
Low-dose "metronomic chemotherapy" with oral cyclophosphamide and methotrexate in metastatic breast cancer: a case report of extraordinarily prolonged clinical benefit / G. Masci, A. Losurdo, C. Gandini, I. Garassino, L. di Tommaso, R. Torrisi, M. Zuradelli, A. Santoro. - In: ECANCERMEDICALSCIENCE. - ISSN 1754-6605. - 6:275(2012), pp. 6.1-6.5. [10.3332/ecancer.2012.275]
Low-dose "metronomic chemotherapy" with oral cyclophosphamide and methotrexate in metastatic breast cancer: a case report of extraordinarily prolonged clinical benefit
L. di Tommaso;
2012
Abstract
We report the case of a 34-year-old woman affected by breast cancer that had metastasized to the bone. She had been treated with oral cyclophosphamide and methotrexate (metronomic chemotherapy) and achieved 3.5 years of clinical remission. To our knowledge, this is the first description of such a prolonged response to therapy. This case report adds weight to known data on metronomic treatment and supports further investigation of this therapy.File | Dimensione | Formato | |
---|---|---|---|
Masci et al. Low dose metronomic chemotherapy.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
1.42 MB
Formato
Adobe PDF
|
1.42 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.